Immunovant, Inc.
NASDAQ:IMVTBiotechnology
+$0.69 today
- Market cap
- $6.86B
- Beta
- 0.79
- P/E (TTM)
- -14.3
- EPS (TTM)
- -$2.48
Volume 0.91M
Average 1.84M
IMVT Net Change in Cash
Combined operating, investing, financing, and currency effects on the cash balance during the period.
Immunovant, Inc.NASDAQ: IMVT
Net Change in Cash · Q2 FY2027 · quarter ended Sep 2026
Net change in cash dips below year-ago levels
Q2 FY2027 net change in cash of $75.52M (cash outflow) fell 2.0% year over year, behind the +309.6% change in trailing-twelve-month net change in cash. Sequentially, it fell 27.6% from the prior quarter.
Context
- Net change in cash increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -2.0% toward the trailing-twelve-month pace of +309.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Net Change in Cash history
USD · from the cash flow
- Latest · FY2026
- 188.14M USD
- Year-over-year change
- +139.3%
- 4-year CAGR
- +19.0%
| Period | Period end | Net Change in Cash | YoY change |
|---|---|---|---|
| FY2026 | 2026-03-31 | 188.14M | +139.3% |
| FY2025 | 2025-03-31 | 78.61M | -69.6% |
| FY2024 | 2024-03-31 | 258.83M | +320.7% |
| FY2023 | 2023-03-31 | (117.29M) | -225.2% |
| FY2022 | 2022-03-31 | 93.67M | — |
Net Change in Cash vs competitors
How IMVT compares with its peers on the latest reported figures
- IMVT's LTM Sep 2026 net change in cash of $200.4M is the 3rd largest of the 11 companies compared; the peer median is $96.6M.
- Its year-over-year change of +309.6% is the 2nd highest of 11, against a peer median of +61.4%.
- Net change in cash amounts to 2824.6% of revenue for IMVT, versus a peer median of 33.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $355.33M | +392.0% | -20.0% | 39.6% | |
| LTM Mar 2026 | $303.67M | +90.6% | +190.9% | — | |
| LTM Sep 2026 | $200.4M | +309.6% | — | 2824.6% | |
| LTM Mar 2026 | $172.33M | +307.6% | — | — | |
| LTM Mar 2026 | $149.83M | +233.4% | — | 64.5% | |
TRAXFirst Tracks Biotherapeutics Inc | FY2025 | $115.12M | +32.1% | — | — |
| LTM Mar 2026 | $78.09M | +242.4% | +20.1% | — | |
| LTM Mar 2026 | $15.2M | -65.0% | +25.9% | — | |
| LTM Mar 2026 | $14.73M | -70.6% | — | 27.4% | |
| LTM Mar 2026 | $1.7M | -69.1% | — | 20.3% | |
| LTM Mar 2026 | $1.57M | -164.9% | -61.9% | — | |
| Peer median (excluding IMVT) | $96.6M | +61.4% | +20.1% | 33.5% | |
Competitors are the stored peer set for IMVT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Mar 2022 | FY2023 Mar 2023 | FY2024 Mar 2024 | FY2025 Mar 2025 | FY2026 Mar 2026 |
|---|---|---|---|---|---|
| Net Income | (156.73M) | (210.96M) | (259.34M) | (413.84M) | (505.61M) |
| Depreciation & Amortization | 126K | 193K | 231K | 377K | 409K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 34.24M | 32.3M | 41.12M | 49.49M | 55.72M |
| Change in Working Capital | 15.14M | (10.85M) | 2.63M | (12.03M) | 42.06M |
| Accounts Receivables | (11.72M) | 12.23M | (4.56M) | 2.97M | (1.4M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 16.25M | (17.12M) | 5.78M | 10.68M | (10.25M) |
| Other Working Capital | 10.61M | (5.95M) | 1.41M | (25.69M) | 53.72M |
| Other Non-Cash Items | 1.11M | 1.13M | 1.13M | 133K | 99K |
| Operating Cash Flow | (106.11M) | (188.19M) | (214.23M) | (375.87M) | (407.31M) |
| Capital Expenditures | (254K) | (197K) | (360K) | (759K) | (8K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (254K) | (197K) | (360K) | (759K) | (8K) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 129K | 70.5M | 472.75M | 450M | 596.26M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 200M | 385K | (318K) | 4.49M | (504K) |
| Financing Cash Flow | 200.13M | 70.89M | 472.43M | 454.49M | 595.76M |
| Effect of Forex Changes | (92K) | 220K | 993K | 747K | (299K) |
| Net Change in Cash | 93.67M | (117.29M) | 258.83M | 78.61M | 188.14M |
| Free Cash Flow | (106.37M) | (188.39M) | (214.59M) | (376.63M) | (407.32M) |
Immunovant, Inc.
NASDAQ:IMVT
Intrinsic Alpha fair value
Locked
Current Price
$33.17
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.